^
Association details:
| Biomarker: | CTNNB1 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Cometriq (cabozantinib capsule) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago and California Consortia (NCI9322/PHL86)
Excerpt:
...evaluated cabozantinib in women with endometrial cancer with progression after chemotherapy....We observed increased frequency of responses with somatic CTNNB1 mutation (4 PRs in 10 pts, median PFS 7.6 mths)...
DOI:
10.1158/1078-0432.CCR-19-2576
